Skip to main content
. 2022 Jun;14(6):1900–1908. doi: 10.21037/jtd-21-1724

Table 1. Baseline characteristics and outcomes of 1-year survivors and non-survivors.

Variables Total (N=76) Survivor (N=52) Non-survivor (N=24) P
Donor variables
   Age (years) 40.1±12.6 39.7±12.3 41.1±13.5 0.665
   PF ratio 426.6±120.0 434.1±109.0 407.5±145.3 0.403
   TLC DR ratio 1.0±0.4 1.1±0.1 0.9±0.7 0.286
Recipient variables
    Age (years) 56.6±10.3 55.2±10.8 59.7±8.0 0.052
    Sex (M) 48 (63.2) 32 (61.5) 16 (66.7) 0.667
    BMI 21.7±4.3 21.2±4.6 22.6±3.5 0.187
    Aetiology 0.470
    DILD 43 (56.6) 29 (55.8) 14 (58.3)
    COPD 7 (9.2) 6 (11.5) 1 (4.2)
    Post-ARDS lung fibrosis 13 (17.1) 8 (15.4) 5 (20.8)
    Pulmonary graft versus host disease 7 (9.2) 6 (11.5) 1 (4.2)
    Bronchiectasis 1 (1.3) 0 1 (4.2)
    Others 5 (6.6) 3 (5.8) 2 (8.3)
   BTT 60 (78.9) 39 (75.0) 21 (87.5) 0.214
   *Adequacy of prophylactic antibiotics 21 (27.6) 13 (25.0) 8 (33.3) 0.450
Preoperative sputum colonisation
   Donor 34 (44.7) 24 (46.2) 10 (41.7) 0.715
   Recipient 28 (36.8) 16 (30.8) 12 (50.0) 0.106
Clinical outcome
   Early PTP 37 (48.7) 20 (38.5) 17 (70.8) 0.009
   Postoperative VFD within 28 days 14.5±9.8 15.4±9.7 12.6±9.9 0.264
   Postoperative ICU stay (days) 20.7±17.6 15.3±12.6 32.3±21.4 0.001

Data is presented as mean ± standard deviations or number (%). *, adequacy of prophylactic antibiotics. Appropriate antimicrobial treatment is defined as the use of agents with in vitro activity against the etiologic pathogens based on our hospital’s diagnostic laboratory results (18). PF ratio, PaO2/FiO2 ratio; TLC DR ratio, total lung capacity donor/recipient ratio; BMI, body mass index; DILD, diffuse interstitial lung disease; COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory distress syndrome; BTT, bridge to transplantation; PTP, post-transplant pneumonia; VFD, ventilator-free day, defined as days alive and free from mechanical ventilation; ICU, intensive care unit.